



BioDelivery Sciences Announces the Hiring of J. Chris Prue as Vice President of Regulatory Affairs and Quality Assurance

October 10, 2014

RALEIGH, N.C., Oct. 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that J. Chris Prue, RPh, MBA has joined BDSI as Vice President of Regulatory Affairs and Quality Assurance.

Mr. Prue brings more than 30 years of pharmaceutical industry experience in regulatory affairs and quality assurance to BDSI. He has held positions of increasing responsibility at The Upjohn Company, Glaxo Inc., GlaxoWellcome and Purdue Pharma LP. Recently he was Vice President of Regulatory Affairs at Atherogenics and then Vice President of Regulatory Affairs and Quality Assurance at Cerenis Therapeutics. Mr. Prue has a Bachelors Degree in Pharmacy as well as a Masters in Business Administration.

"We are excited to have Chris join our team as we continue to expand our capabilities to meet BDSI's growing needs," said Dr. Andrew Finn, Executive Vice President of Product Development, to whom Mr. Prue will report. "Over his pharmaceutical industry career, Chris has had extensive experience with analgesic and opioid development and has worked closely with the Division of Anesthetic and Analgesic Products at the FDA. Given Chris' strong regulatory and quality assurance expertise, BDSI's Research and Development group has been reorganized so that both Regulatory Affairs and Quality Assurance will report to him. Dr. Adrian Hepner, who led BDSI through the successful FDA approval of BUNAVAIL, has assumed new responsibilities as Vice President of Clinical Research and Medical Affairs."

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA[®]) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.

BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.

BDSI's headquarters is located in Raleigh, North Carolina.

For more information visit www.bdsi.com.

BDSI can now be followed on Facebook ([Facebook.com/BioDeliverySI](https://www.facebook.com/BioDeliverySI)) and Twitter ([Twitter.com/BioDeliverySI](https://twitter.com/BioDeliverySI))

Cautionary Note on Forward-Looking Statements

This press release, the event described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto (including, without limitation, at the presentations described herein) contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the performance of the Company officer described herein) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

BDSI[®] and BEMA[®] are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences logo and BUNAVAIL[™] are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners.

© 2014 BioDelivery Sciences International, Inc. All rights reserved.

SOURCE BioDelivery Sciences International, Inc.

For further information: Investors: Brian Korb, Senior Vice President, The Trout Group LLC, (646) 378-2923, bkorb@troutgroup.com, Al Medwar, Vice President, Marketing and Corporate Development, BioDelivery Sciences International, Inc., 919-582-9050, amedwar@bdsi.com, Media: Susan Forman/Laura Radocaj, Dian Griesel Int'l., 212-825-3210, sforman@dgicomm.com, lradocaj@dgicomm.com